Table 2.
Non-CYP drug-drug interactions.
| Drug/Drug Interaction | Severity | Action | Mechanism |
| ALBUTEROL SULFATE / CARVEDILOL | Major | Avoid combination | Beta-Blockers may diminish the bronchodilatory effect of Beta2-Agonists. |
| CARVEDILOL / FLUTICASONE & VILANTEROL | Major | Avoid combination | Beta-Blockers may diminish the bronchodilatory effect of Beta2-Agonists. |
| ALLOPURINOL / WARFARIN SODIUM | Moderate | Consider modification | Allopurinol may enhance the anticoagulant effect of Vitamin K Antagonists. |
| ATORVASTATIN CALCIUM / DILTIAZEM HCL (AC/DHCL) | Major | Consider modification | DHCL may increase the serum concentration of AC. AC may increase the serum concentration of DHCL. |
| CARVEDILOL / TAMSULOSIN HCL | Moderate | Consider modification | Beta-Blockers may enhance the orthostatic hypotensive effect of Alphal-Blockers |
| FUROSEMIDE / NAPROXEN | Moderate | Consider modification | Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics |
| NAPROXEN/ WARFARIN SODIUM | Moderate | Consider modification | NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists |